Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Jun 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to relieve pain in patients with painful bone tumors that have spread from other parts of the body, known as metastases. The researchers want to see if giving a higher dose of radiation (40-50 Gy) in ten treatments can help more patients feel significant pain relief within one month. They believe that this approach may lead to better and longer-lasting results for those suffering from both painful bone and non-bone metastases.
To join the trial, participants need to be at least 18 years old and have a confirmed diagnosis of cancer with evidence of bone or non-bone metastases. They should have a pain score of 3 or higher and a life expectancy of at least six months. Women who can become pregnant must agree to use contraception, and men must also follow similar guidelines. Participants will receive the radiation treatment and be monitored for their pain relief and overall response. This trial is actively recruiting patients, and it aims to provide valuable insights into managing pain from metastatic cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have provided signed informed consent for the trial
- • Aged ≥18 years at the time of informed consent
- • Histologic proof of malignancy
- • Radiologic or histologic evidence of bone metastases or non-bone metastases
- • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3
- • Pain Score ≥ 3
- • Life expectancy of six months or more
- • Willing and able to comply with all aspects of the protocol
- • A female participant is eligible to participate if she is not pregnant and not breastfeeding
- • Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
- • A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.
- Exclusion Criteria:
- • Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)
- • Spinal metastasis
- • Active compression of spinal cord/cauda equina
- • Previous RT or SBRT to the same site
- • \> 3 sites requiring radiation treatment
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Brunswick, New Jersey, United States
New Brunswick, New Jersey, United States
Hamilton, New Jersey, United States
Livingston, New Jersey, United States
Somerset, New Jersey, United States
Toms River, New Jersey, United States
Lakewood, New Jersey, United States
Patients applied
Trial Officials
Matthew P Deek, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials